Anumana
Anumana is an AI-driven health technology company focused on improving patient care in the cardiac care continuum through advanced AI solutions and algorithms, including several FDA-cleared and breakthrough-designated devices.
Company History
Anumana is an AI-driven health technology company that originated from nference. The company focuses on building and commercializing AI solutions to advance patient care, particularly throughout the cardiac care continuum. Over the years, Anumana has established itself as a leader in the integration of AI and healthcare, utilizing the largest combined dataset of electrophysiological data, longitudinal patient history, and outcomes in the world to drive its innovations.
AI Solutions and Algorithms
Anumana specializes in AI solutions for early diagnosis and improved outcomes of cardiovascular diseases. The company’s technologies include ECG-AI algorithms for early disease detection and EGM-AI algorithms that enhance electrophysiology procedures. Anumana's ECG-AI LEF algorithm, which detects low left ventricular ejection fraction using 12-lead ECG data, has received FDA clearance. Additionally, Anumana's algorithms for pulmonary hypertension, cardiac amyloidosis, and hyperkalemia have received FDA Breakthrough Device Designation.
Clinical Validation and FDA Clearances
Anumana transforms research-grade algorithms into medical devices, undergoing rigorous clinical validation to achieve regulatory clearances. The ECG-AI LEF algorithm, developed with Mayo Clinic and nference, has undergone evaluation in over 25 studies and demonstrated significant sensitivity and specificity. It received U.S. FDA clearance in September 2023. Other algorithms, such as those for pulmonary hypertension and cardiac amyloidosis, have also attained Breakthrough Device Designation, reflecting their potential to improve patient outcomes.
Data and Evidence Generation
Anumana leverages a comprehensive evidence generation platform called nSights, which includes data from 11 million patients spanning over 20 years. This extensive dataset supports the company's development of AI-driven solutions that empower clinicians to diagnose and treat cardiovascular diseases more effectively. Anumana's pipeline is supported by more than 75 peer-reviewed publications, underscoring the potential impact of their technologies on early disease detection and prognosis improvement.
Collaborations and Strategic Partnerships
In a strategic move to enhance its AI capabilities, Anumana has launched a multi-year collaboration with Novartis Pharmaceuticals Corporation. This partnership aims to develop AI-powered software solutions for the early detection and intervention of cardiovascular diseases. Such strategic alliances help Anumana expand its reach and effectiveness in improving cardiovascular patient care through innovative AI technologies.